<DOC>
	<DOCNO>NCT00622674</DOCNO>
	<brief_summary>RATIONALE : Bortezomib may stop growth tumor cell block enzymes need cell growth . Monoclonal antibody , cetuximab , block tumor growth different way . Some block ability tumor cell grow spread . Others find tumor cell help kill carry tumor-killing substance . Giving bortezomib together cetuximab may kill tumor cell . PURPOSE : This phase I trial study side effect best dose bortezomib give together cetuximab treat patient advance solid tumor .</brief_summary>
	<brief_title>Bortezomib Cetuximab Treating Patients With Advanced Solid Tumors</brief_title>
	<detailed_description>OBJECTIVES : Primary - To determine maximum tolerate dose bortezomib give together cetuximab patient advance solid tumor express epidermal growth factor receptor ( EGFR ) . Secondary - To obtain preliminary information anti-tumor activity bortezomib cetuximab . OUTLINE : This dose-escalation study bortezomib . Patients receive bortezomib intravenously ( IV ) day 1 8 cetuximab IV 60-90 minute day 1 , 8 , 15 . Treatment repeat every 21 day 6 course absence disease progression unacceptable toxicity . After maximum tolerate dose ( MTD ) determine , additional 10 patient treated MTD . After completion study treatment , patient follow periodically 1 year .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Sarcoma</mesh_term>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Kidney Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<criteria>Diagnosis solid tumor overexpresses epidermal growth factor receptor ( EGFR ) include , limited , follow : Breast cancer Lung cancer Colon cancer Pancreatic cancer Head neck cancer Kidney cancer Sarcoma Advanced disease Must fail become intolerant prior standard therapy longer likely respond therapy Measurable nonmeasurable disease ECOG performance status 01 ANC ≥ 1,500/mm³ Platelet count &gt; 100,000/mm³ Hemoglobin &gt; 9 g/dL Bilirubin &lt; 1.5 time upper limit normal ( ULN ) Alkaline phosphatase &lt; 3.0 time ULN ( 5.0 time ULN liver tumor involvement ) Aspartate aminotransferase ( AST ) alanine aminotransferase ( *ALT ) &lt; 3.0 time upper limit normal ( ULN ) ( 5.0 time ULN liver tumor involvement ) Creatinine clearance &gt; 30 mL/min Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception 3 month completion study treatment Recovered prior therapy Prior systemic chemotherapy , immunotherapy , biological therapy allow At least 14 day since prior radiotherapy systemic therapy At least 30 day since prior investigational agent At least 14 day since prior investigational drug ( reason treatment cancer ) Untreated symptomatic central nervous system ( CNS ) metastases Concurrent serious systemic disorder ( e.g. , active infection ) , opinion investigator , would compromise safety patient compromise patient 's ability complete study Uncontrolled diabetes Myocardial infarction within past 6 month New York Heart Association ( NYHA ) class III IV heart failure Uncontrolled angina Severe uncontrolled ventricular arrhythmias Evidence acute ischemia active conduction system abnormalities ECG Peripheral neuropathy Common Terminology Criteria Adverse Events ( CTCAE ) grade &gt; 2 Known hypersensitivity bortezomib , boron , mannitol Serious medical psychiatric illness likely interfere study participation Prior bortezomib and/or cetuximab Concurrent filgrastim ( GCSF ) hematologic support course 1 study treatment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2010</verification_date>
	<keyword>recurrent breast cancer</keyword>
	<keyword>recurrent non-small cell lung cancer</keyword>
	<keyword>recurrent small cell lung cancer</keyword>
	<keyword>recurrent colon cancer</keyword>
	<keyword>recurrent pancreatic cancer</keyword>
	<keyword>recurrent head neck cancer</keyword>
	<keyword>recurrent sarcoma</keyword>
	<keyword>recurrent kidney cancer</keyword>
	<keyword>recurrent renal cell cancer</keyword>
</DOC>